Stockpolly
Search
ELTX · NASDAQ · Biotechnology

Elicio Therapeutics

Develops AMP-enabled cancer immunotherapies centered on the ELI-002 mutant-KRAS program.

$2.80
Pre-market+0.10 (+3.51%)
At close$2.71(−4.75%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
119101110131010891010
Research & development7688711875577
433333333444
General & administrative433330333444
Other expenses000000000000
Operating income−11−9−10−11−10−13−11−10−8−9−11−10
00−24−8−100−21−12
Interest income000000000000
Interest expense000000000000
Other non-operating income002−480002−112
Income before tax−11−9−12−7−19−14−11−11−10−8−12−8
Net income from continuing operations−11−9−12−7−19−14−11−11−10−8−12−8
Net income−11−9−12−7−19−14−11−11−10−8−12−8
EPS, basic−$2.61−$0.93−$1.15−$0.64−$1.39−$1.15−$0.87−$0.66−$0.60−$0.45−$0.65−$0.43
EPS, diluted−$2.61−$0.93−$1.15−$0.64−$1.39−$1.15−$0.87−$0.66−$0.60−$0.45−$0.65−$0.43
Weighted average shares, basic41010111412131617151819
Weighted average shares, diluted41010111412131617151819
EBITDA−10−9−12−7−18−13−11−10−9−7−11−13
Depreciation & amortization000000000000
EBIT−11−9−12−7−19−14−11−10−10−7−11−13